Clinical Trial Update: A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two dosing schedules of atezolizumab in combination with gemcitabine and cisplatin as first-line therapy for metastatic urothelial carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• Platinol (cisplatin)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Urothelial Carcinoma, Locally Advanced | Phase 2 | Status: ACTIVE_NOT_RECRUITING